AFP
ACHN

Ausdal Financial Partners’s Achillion Pharmaceuticals ACHN Stock Holding History

Ausdal Financial Partners’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,000
Closed -$54K – 1150
2015
Q4 		$54K Buy
+5,000
New +$45.5K 0.03% 436

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ausdal Financial Partners's ACHN Position: Q1 2016 in Review

Ausdal Financial Partners sold out of Achillion Pharmaceuticals (ACHN) in Q1 2016, closing a stake of 5,000 shares — an estimated $54K sold.

Ausdal Financial Partners first reported a position in ACHN in Q4 2015 and held it in 1 quarter. The position peaked at $54K in Q4 2015. 153 funds tracked by Wall St. Rank hold ACHN as of Q1 2016.

  • Ausdal Financial Partners reported no remaining Achillion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Ausdal Financial Partners sold 5,000 Achillion Pharmaceuticals shares in Q1 2016, an estimated $54K.
  • Ausdal Financial Partners first reported a position in Achillion Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Ausdal Financial Partners's Achillion Pharmaceuticals position peaked at $54K in Q4 2015.
  • 153 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2016.

Based on Ausdal Financial Partners's 13F filing for Q1 2016, filed 5 May 2016.